Transplanting HCV-infected kidneys into uninfected recipients

New England Journal of Medicine

Volumn 377, Issue 11, 2017, Pages 1104-

  Goldberg, David S ^a   Abt, Peter L ^a   Reese, Peter P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; SOFOSBUVIR;

ACUTE KIDNEY FAILURE; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; HEALTH CARE ACCESS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LETTER; PRIORITY JOURNAL; VIRUS TRANSMISSION; KIDNEY;

HEPATITIS C; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION;

EID: 85029431420     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1709315     Document Type: Letter

References (4)

1. Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 2016;16:1588-95.
2. Ellingson K, Seem D, Nowicki M, Strong DM, Kuehnert MJ. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011;11:1201-8.
3. Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant 2017 May 29 (Epub ahead of print).
4. Leithead JA, Rajoriya N, Gunson BK, Muiesan P, Ferguson JW. The evolving use of higher risk grafts is associated with an increased incidence of acute kidney injury after liver transplantation. J Hepatol 2014;60:1180-6.